Molecular Biology of Basal and Squamous Cell Carcinomas

  • Jingwu Xie
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 624)


Basal cell carcinomas and Squamous cell carcinomas are the two most common human cancers. The incidence of these two types of cancer is estimated to double within 20 years. Identification of the key molecular events is critical in helping us design novel strategies to treat and to prevent these cancers. For example, identification of hedgehog signaling activation has opened up many opportunities for targeted therapy and prevention of basal cell carcinomas. Significant progress has also been made in our understanding of squamous cell carcinomas of the skin. In this chapter, we will focus on major recent developments in our understanding of basal cell carcinomas and squamous cell carcinomas at the molecular levels and their clinical implications.


Squamous Cell Carcinoma Basal Cell Carcinoma Actinic Keratose Sonic Hedgehog Hedgehog Signaling 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Christenson LJ, Borrowman TA, Vachon CM et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005; 294:681–90.PubMedCrossRefGoogle Scholar
  2. 2.
    Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57:43–66.PubMedCrossRefGoogle Scholar
  3. 3.
    Hahn H, Wicking C, Zaphiropoulous PG et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996; 85:841–51.PubMedCrossRefGoogle Scholar
  4. 4.
    Johnson RL, Rothman AL, Xie J et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272:1668–71.PubMedCrossRefGoogle Scholar
  5. 5.
    Epstein E. Genetic determinants of basal cell carcinoma risk. Med Pediatr Oncol 2001; 36:555–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001; 411:349–54.PubMedCrossRefGoogle Scholar
  7. 7.
    Chuang PT, McMahon AP. Vertebrate Hedgehog signalling modulated by induction of a Hedgehog-binding protein. Nature 1999; 397:617–21.PubMedCrossRefGoogle Scholar
  8. 8.
    Jia J, Jiang J. Decoding the Hedgehog signal in animal development. Cell Mol Life Sci 2006; 63:1249–65.PubMedCrossRefGoogle Scholar
  9. 9.
    Rohatgi R, Milenkovic L, Scott MP. Patchedl regulates hedgehog signaling at the primary cilium. Science 2007; 317:372–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Corbit KC, Aanstad P, Singla V et al. Vertebrate Smoothened functions at the primary cilium. Nature 2005; 437:1018–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Pasca di Magliano M, Hebrok M. Hedgehog signalling in cancer formation and maintenance. Nat Rev Cancer 2003; 3:903–11.PubMedCrossRefGoogle Scholar
  12. 12.
    Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 1987; 66:98–113.PubMedCrossRefGoogle Scholar
  13. 13.
    Gorlin RJ. Living history-biography: from oral pathology to craniofacial genetics. Am J Med Genet 1993; 46:317–34.PubMedCrossRefGoogle Scholar
  14. 14.
    Gorlin RJ, Goltz RW. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med 1960; 262:908–12.PubMedGoogle Scholar
  15. 15.
    Gailani MR, Bale SJ, Leffell DJ et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 1992; 69:111–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Gailani MR, Stahle-Backdahl M, Leffell DJ et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet 1996; 14:78–81.PubMedCrossRefGoogle Scholar
  17. 17.
    Goodrich LV, Johnson RL, Milenkovic L et al. Conservation of the hedgehog/patched signaling pathway from flies to mice: induction of a mouse patched gene by Hedgehog. Genes Dev 1996; 10:301–12.PubMedCrossRefGoogle Scholar
  18. 18.
    Lindstrom E, Shimokawa T, Toftgard R et al. PTCH mutations: distribution and analyses. Hum Mutat 2006; 27:215–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Bale AE, Yu, KP. The hedgehog pathway and basal cell carcinomas. Hum Mol Genet 2001; 10:757–62.PubMedCrossRefGoogle Scholar
  20. 20.
    Goodrich LV, Milenkovic L, Higgins KM et al. Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997; 277:1109–13.PubMedCrossRefGoogle Scholar
  21. 21.
    Hahn H, Wojnowski L, Zimmer AM et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 1998; 4:619–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Aszterbaum M, Beech J, Epstein EH. Ultraviolet radiation mutagenesis of hedgehog pathway genes in basal cell carcinomas. J Investig Dermatol Symp Proc 1999; 4:41–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Xie J, Murone M, Luoh SM et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391:90–2.PubMedCrossRefGoogle Scholar
  24. 24.
    Lam CW, Xie J, To KF et al. A frequent activated smoothened mutation in sporadic basal cell carcinomas. Oncogene 1999; 18:833–6.PubMedCrossRefGoogle Scholar
  25. 25.
    Reifenberger J, Wolter M, Knobbe CB et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol 2005; 152:43–51.PubMedCrossRefGoogle Scholar
  26. 26.
    Reifenberger J, Wolter M, Weber RG et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998; 58:1798–803.PubMedGoogle Scholar
  27. 27.
    Couve-Privat S, Bouadjar B, Avril MF et al. Significantly high levels of ultraviolet-specific mutations in the smoothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients. Cancer Res 2002; 62:7186–9.PubMedGoogle Scholar
  28. 28.
    Xic J, Aszterbaum M, Zhang X et al. A role of PDGFRalpha in basal cell carcinoma proliferation. Proc Natl Acad Sci USA 2001; 98:9255–9.CrossRefGoogle Scholar
  29. 29.
    Athar M, Li C, Tang X et al. Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res 2004; 64:7545–52.PubMedCrossRefGoogle Scholar
  30. 30.
    Williams JA, Guicherit OM, Zaharian BI et al. Identification of a small molecule inhibitor of the hedgehog signaling pathway: effects on basal cell carcinoma-like lesions. Proc Natl Acad Sci USA 2003; 100:4616–21.PubMedCrossRefGoogle Scholar
  31. 31.
    Bijlsma MF, Spek CA, Zivkovic D et al. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol 2006; 4:e232.PubMedCrossRefGoogle Scholar
  32. 32.
    Kasper M, Schnidar H, Neill GW et al. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol Cell Biol 2006; 26:6283–98.PubMedCrossRefGoogle Scholar
  33. 33.
    Riobo NA, Haines GM, Emerson CP. Protein kinase C-delta and mitogen-activated protein/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signaling. Cancer Res 2006; 66:839–45.PubMedCrossRefGoogle Scholar
  34. 34.
    Riobo NA, Lu K, Ai X et al. Phosphoinositide 3-kinase and Akt are essential for Sonic Hedgehog signaling. Proc Natl Acad Sci USA 2006; 103:4505–10.PubMedCrossRefGoogle Scholar
  35. 35.
    Kenney AM, Widlund HR, Rowitch DH. Hedgehog and PI-3 kinase signaling converge on Nmycl to promote cell cycle progression in cerebellar neuronal precursors. Development 2004; 131:217–28.PubMedCrossRefGoogle Scholar
  36. 36.
    Bigelow RL, Jen EY, Delehedde M et al. Sonic hedgehog induces epidermal growth factor dependent matrix infiltration in HaCaT keratinocytes. J Invest Dermatol 2005; 124:457–65.PubMedCrossRefGoogle Scholar
  37. 37.
    Riobo NA, Lu K, Emerson CP. Hedgehog signal transduction: signal integration and cross talk in development and cancer. Cell Cycle 2006; 5:1612–5.PubMedGoogle Scholar
  38. 38.
    Ji Z, Mei FC, Xie J et al. Oncogenic kras supresses GLI1 degradation and activates hedgehog signaling pathway in pancreatic cancer cells. J Biol Chem 2007.Google Scholar
  39. 39.
    Sheng T, Chi S, Zhang X et al. Regulation of Gli1 localization by the cAMP/protein kinase A signaling axis through a site near the nuclear localization signal. J Biol Chem 2006; 281:9–12.PubMedCrossRefGoogle Scholar
  40. 40.
    Caserta TM, Kommagani R, Yuan Z et al. p63 overexpression induces the expression of Sonic Hedgehog. Mol Cancer Res 2006; 4:759–68.PubMedCrossRefGoogle Scholar
  41. 41.
    Uziel T, Zindy F, Xie S et al. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 2005; 19:2656–67.PubMedCrossRefGoogle Scholar
  42. 42.
    Mimeault M, Johansson SL, Vankatraman G et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 2007; 6:967–78.PubMedCrossRefGoogle Scholar
  43. 43.
    Quaedvlieg PJ, Tirsi E, Thissen MR et al. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006; 16:335–9.PubMedGoogle Scholar
  44. 44.
    Takata M, Saida T. Early cancers of the skin: clinical, histopathological and molecular characteristics. Int J Clin Oncol 2005; 10:391–7.PubMedCrossRefGoogle Scholar
  45. 45.
    Boukamp P. Nonmelanoma skin cancer: what drives tumor development and progression? Carcinogenesis 2005; 26:1657–67.PubMedCrossRefGoogle Scholar
  46. 46.
    Tsai KY, Tsao H. The genetics of skin cancer. Am J Med Genet C Semin Med Genet 2004; 131C:82–92.PubMedCrossRefGoogle Scholar
  47. 47.
    Ridky TW, Khavari PA. Pathways sufficient to induce epidermal carcinogenesis. Cell Cycle 2004; 3:621–4.PubMedGoogle Scholar
  48. 48.
    Smith-McCune K, Zhu YH, Hanahan D et al. Cross-species comparison of angiogenesis during the premalignant stages of squamous carcinogenesis in the human cervix and K14-HPV16 transgenic mice. Cancer Res 1997; 57:1294–300.PubMedGoogle Scholar
  49. 49.
    Brown VL, Harwood CA, Crook T et al. p16INK4a and p14ARF tumor suppressor genes are commonly inactivated in cutaneous squamous cell carcinoma. J Invest Dermatol 2004; 122:1284–92.PubMedCrossRefGoogle Scholar
  50. 50.
    Blokx WA, Ruiter DJ, Verdijk MA et al. INK4-ARF and p53 mutations in metastatic cutaneous squamous cell carcinoma: case report and archival study on the use of Ink4a-ARF and p53 mutation analysis in identification of the corresponding primary tumor. Am J Surg Pathol 2005; 29:125–30.PubMedCrossRefGoogle Scholar
  51. 51.
    Blokx WA, de Jong EM, de Wilde PC et al. P16 and p53 expression in (pre) malignant epidermal tumors of renal transplant recipients and immunocompetent individuals. Mod Pathol 2003; 16:869–78.PubMedCrossRefGoogle Scholar
  52. 52.
    Saridaki Z, Liloglou T, Zafiropoulos A et al. Mutational analysis of CDKN2A genes in patients with squamous cell carcinoma of the skin. Br J Dermatol 2003; 148:638–48.PubMedCrossRefGoogle Scholar
  53. 53.
    Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002; 2:910–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Pickering MT, Kowalik TF. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene 2006; 25:746–55.PubMedCrossRefGoogle Scholar
  55. 55.
    Soufir N, Moles JP, Vilmer C et al. P16 UV mutations in human skin epithelial tumors. Oncogene 1999; 18:5477–81.PubMedCrossRefGoogle Scholar
  56. 56.
    Giglia-Mari G, Sarasin A. TP53 mutations in human skin cancers. Hum Mutat 2003; 21:217–28.PubMedCrossRefGoogle Scholar
  57. 57.
    Bolshakov S, Walker CM, Strom SS et al. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res 2003; 9:228–34.PubMedGoogle Scholar
  58. 58.
    Kim MY, Park HJ, Baek SC et al. Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias. J Dermatol Sci 2002; 29:1–9.PubMedCrossRefGoogle Scholar
  59. 59.
    Ansarin H, Daliri M, Soltani-Arabshahi R. Expression of p53 in aggressive and non-aggressive histologic variants of basal cell carcinoma. Eur J Dermatol 2006; 16:543–7.PubMedGoogle Scholar
  60. 60.
    D’Errico M, Calcagnile AS, Corona R et al. p53 mutations and chromosome instability in basal cell carcinomas developed at an early or late age. Cancer Res 1997; 57:747–52.PubMedGoogle Scholar
  61. 61.
    Wiseman SM, Stoler DL, Anderson GR. The role of genomic instability in the pathogenesis of squamous cell carcinoma of the head and neck. Surg Oncol Clin N Am 2004; 13:1–11.PubMedCrossRefGoogle Scholar
  62. 62.
    Perez-Losada J, Mao JH, Balmain A. Control of genomic instability and epithelial tumor development by the p53-Fbxw7/Cdc4 pathway. Cancer Res 2005; 65:6488–92.PubMedCrossRefGoogle Scholar
  63. 63.
    Duensing A, Duensing S. Guilt by association? p53 and the development of aneuploidy in cancer. Biochem Biophys Res Commun 2005; 331:694–700.PubMedCrossRefGoogle Scholar
  64. 64.
    Pelisson I, Soler C, Chardonnet Y et al. A possible role for human papillomaviruses and c-myc, c-Ha-ras and p53 gene alterations in malignant cutaneous lesions from renal transplant recipients. Cancer Detect Prev 1996; 20:20–30.PubMedGoogle Scholar
  65. 65.
    Aziz MH, Manoharan HT, Verma AK. Protein kinase C epsilon, which sensitizes skin to sun’s UV radiation-induced cutaneous damage and development of squamous cell carcinomas, associates with Stat3. Cancer Res 2007; 67:1385–94.PubMedCrossRefGoogle Scholar
  66. 66.
    Quadros MR, Peruzzi F, Kari C et al. Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res 2004; 64:3934–9.PubMedCrossRefGoogle Scholar
  67. 67.
    Dudley AC, Thomas D, Best J et al. A VEGF/JAK2/STAT5 axis may partially mediate endothelial cell tolerance to hypoxia. Biochem J 2005; 390:427–36.PubMedCrossRefGoogle Scholar
  68. 68.
    Budunova IV, Perez P, Vaden VR et al. Increased expression of p50-NF-kappaB and constitutive activation of NF-kappaB transcription factors during mouse skin carcinogenesis. Oncogene 1999; 18:7423–31.PubMedCrossRefGoogle Scholar
  69. 69.
    Loercher A, Lee TL, Ricker JL et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004; 64:6511–23.PubMedCrossRefGoogle Scholar
  70. 70.
    Duffey DC, Chen Z, Dong G et al. Expression of a dominant-negative mutant inhibitor-kappaBalpha of nuclear factor-kappaB in human head and neck squamous cell carcinoma inhibits survival, proinflammatory cytokine expression and tumor growth in vivo. Cancer Res 1999; 59:3468–74.PubMedGoogle Scholar
  71. 71.
    Verma AK, Wheeler DL, Aziz MH et al. Protein kinase Cepsilon and development of squamous cell carcinoma, the nonmelanoma human skin cancer. Mol Carcinog 2006; 45:381–8.PubMedCrossRefGoogle Scholar
  72. 72.
    Bremner R, Kemp CJ, Balmain A. Induction of different genetic changes by different classes of chemical carcinogens during progression of mouse skin tumors. Mol Carcinog 1994; 11:90–7.PubMedCrossRefGoogle Scholar
  73. 73.
    DiGiovanni J. Genetic factors controlling responsiveness to skin tumor promotion in mice. Prog Clin Biol Res 1995; 391:195–212.PubMedGoogle Scholar
  74. 74.
    Hirst GL, Balmain A. Forty years of cancer modelling in the mouse. Eur J Cancer 2004; 40:1974–80.PubMedCrossRefGoogle Scholar
  75. 75.
    Rebel H, Mosnier LO, Berg RJ et al. Early p53-positive foci as indicators of tumor risk in ultraviolet-exposed hairless mice: kinetics of induction, effects of DNA repair deficiency and p53 heterozygosity. Cancer Res 2001; 61:977–83.PubMedGoogle Scholar
  76. 76.
    Rebel H, Kram N, Westerman A et al. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice. Carcinogenesis 2005; 26:2123–30.PubMedCrossRefGoogle Scholar
  77. 77.
    Ahsan H, Aziz MH, Ahmad N. Ultraviolet B exposure activates Stat 3 signaling via phosphorylation at tyrosine705 in skin of SKH1 hairless mouse: a target for the management of skin cancer? Biochem Biophys Res Commun 2005; 333:241–6.PubMedCrossRefGoogle Scholar
  78. 78.
    Wakabayashi Y, Mao JH, Brown K et al. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature 2007; 445:761–5.PubMedCrossRefGoogle Scholar
  79. 79.
    Roth JA. Adenovirus p53 gene therapy. Expert Opin Biol Ther 2006; 6:55–61.PubMedCrossRefGoogle Scholar
  80. 80.
    McCormick F. Cancer-specific viruses and the development of ONYX-015. Cancer Biol Ther 2003; 2:S157–60.PubMedGoogle Scholar
  81. 81.
    Lane DP, Lain S. Therapeutic exploitation of the p53 pathway. Trends Mol Med 2002; 8;S38–42.PubMedCrossRefGoogle Scholar
  82. 82.
    Vassilev LT. p53 Activation by small molecules: application in oncology. J Med Chem 2005; 48:4491–9.PubMedCrossRefGoogle Scholar
  83. 83.
    Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell 2002; 2:103–12.PubMedCrossRefGoogle Scholar
  84. 84.
    Green CL, Khavari PA. Targets for molecular therapy of skin cancer. Semin Cancer Biol 2004; 14:63–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Ozols RF, Herbst RS, Colson YL et al. Clinical cancer advances 2006: major research advances in cancer treatment, prevention and screening—a report from the American Society of Clinical Oncology. J Clin Oncol 2007; 25:146–62.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2008

Authors and Affiliations

  • Jingwu Xie
    • 1
  1. 1.Department of Pharmacology and ToxicologySealy Center for Cancer Cell Biology University of Texas Medical BranchGalvestonUSA

Personalised recommendations